Oncimmune (LON:ONC) Hits New 1-Year Low at $42.00

ETFS

Oncimmune Holdings plc (LON:ONCGet Rating) shares reached a new 52-week low on Friday . The company traded as low as GBX 42 ($0.49) and last traded at GBX 42 ($0.49), with a volume of 18553 shares. The stock had previously closed at GBX 44.50 ($0.52).

Oncimmune Price Performance

The company has a market cap of £29.18 million and a price-to-earnings ratio of -4.12. The business has a 50-day moving average price of GBX 59.30 and a 200 day moving average price of GBX 80.48. The company has a current ratio of 0.66, a quick ratio of 0.63 and a debt-to-equity ratio of 677.62.

Insider Activity

In other news, insider Adam Hill bought 8,005 shares of the business’s stock in a transaction dated Wednesday, September 21st. The stock was bought at an average price of GBX 62 ($0.73) per share, for a total transaction of £4,963.10 ($5,832.08).

Oncimmune Company Profile

Want More Great Investing Ideas?

(Get Rating)

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.

Featured Articles

Receive News & Ratings for Oncimmune Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Oncimmune and related companies with MarketBeat.com’s FREE daily email newsletter.

Products You May Like